• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Profits slide for Hill-Rom as it names Bard vet Groetelaars CEO

Profits slide for Hill-Rom as it names Bard vet Groetelaars CEO

April 27, 2018 By Brad Perriello

Hill-RomHill-Rom Holdings (NYSE:HRC) said today that it’s naming C.R. Bard veteran John Groetelaars to be its new chief executive, effective May 14, as it reported a fiscal second-quarter profit slide on results that still managed to top the consensus.

Groetelaars is succeeding John Greisch, who in January announced his plans to retire by the fiscal third quarter. His replacement was president of the interventional business at Becton Dickinson (NYSE:BDX) after joining following the Bard acquisition last year, the Chicago-based company said.

In a separate release Hill-Rom posted profits of $28.5 million, or 42¢ per share, on sales of $710.5 million for the three months ended March 31, for a bottom-line slide of -17.2% on sales growth of 4.7% compared with the same period last year.

Still, adjusted to exclude one-time items, earnings per share beat the consensus estimate by 3¢, coming in at $1.05, prompting Hill-Rom to raise the low end of its full-year earnings guidance. Analysts on Wall Street were looking for sales of $705.5 million.

“Hill-Rom’s financial performance continues to reflect solid execution on our strategic priorities. With sustained momentum across our diversified core business, we are confident in our ability to drive accelerated revenue growth,” Greisch said in prepared remarks. “Innovation, international momentum, and strategic investments to strengthen our commercial capabilities and operational execution will continue to drive enhanced value for patients, caregivers and our shareholders.”

Hill-Rom said it now expects to report adjusted EPS of $4.60 to $4.65 this year, up from prior guidance of $4.57 to $4.65, on sales growth of 3% to 4%.

HRC shares were down -3.6% at $84.87 apiece today in late-morning trading.

Filed Under: MassDevice Earnings Roundup, Wall Street Beat Tagged With: Hillrom

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy